{"id":"W4402514945","doi":"10.1038/s41591-024-03261-7","title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Eisai; Jazz Pharmaceuticals; Helsinn; Chugai Pharmaceutical; Seagen; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001300659,0.000818288,0.001047903,0.0002382192,0.0002447886,0.0005979568,0.0004429169,0.0006072843,0.002061069],"category_scores_gemma":[0.0005574113,0.0001887647,0.000672474,0.000246573,0.0004737168,0.0004200019,0.0002403448,0.001393745,0.0003617947],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000594646,"about_ca_system_score_gemma":0.0007525772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005672854,"about_ca_topic_score_gemma":0.001496091,"domain_scores_codex":[0.9997591,0.0001334711,0.00001100275,0.00002695294,0.00002666277,0.00004280851],"domain_scores_gemma":[0.9997661,0.00004460178,0.00004174689,0.00001879631,0.00001817026,0.0001107646],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7914408,0.03019499,0.008533897,0.0009832421,0.001487499,0.000422418,0.0001935781,0.002296217,0.02869245,0.0004248572,0.005908014,0.129422],"study_design_scores_gemma":[0.7167692,0.2561574,0.01514722,0.00006694606,0.0005400901,0.000361136,0.00004743105,0.001638464,0.004046042,0.0003963873,0.004804868,0.00002487299],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941359,0.002717015,0.0001626828,0.0003652141,0.00006600832,0.0007391619,0.0005491751,0.00003707127,0.001227746],"genre_scores_gemma":[0.9900978,0.003246526,0.000725476,0.0006355362,0.0001570898,0.00105694,0.001748795,0.00001522473,0.002316684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002061069,"threshold_uncertainty_score":0.006894946,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01226947485604996,"score_gpt":0.3775639384676909,"score_spread":0.365294463611641,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}